Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and the EU, with a robust pipeline of 30 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and the EU. Luye Pharma is a global cutting edge company in terms of research into new drug delivery technologies, such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.
Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., the EU and Japan, as well as fast growing emerging markets.
Mr Gilbert PfundSenior Manager Business Development and Licensing
Max Zeller Söhne AG
Max Zeller Söhne AG specialises in the development, production and marketing of phyto-pharmaceuticals with clinically proven efﬁcacy, safety and tolerability.
Zeller is a leader in the Swiss market for phyto-pharmaceuticals and one of the few companies that controls the entire value chain from seed to ﬁnished product. At the Zeller sites in Romanshorn and Uttwil (VitaPlant), there are 135 employees in diverse disciplines such as biology, agriculture, process engineering, pharmacy and medicine. Patients beneﬁt from Zeller’s phyto-pharmaceuticals both in Switzerland and worldwide.
Dr Si ChenBusiness Development Manager
Ms Yulia KirschnerDirector International Division
Medis doo is the leading commercialization partner for innovative companies in the CSEE region. With 29 years of experience, we have proven our capabilities and reliability to many most admired pharmaceutical/biotech companies. We have the highest financial rating, 300+ employees and strong presence in hospital and retail.
Medis is looking for new cutting-edge medical solutions, to address unmet medical needs in the CSEE.
Anja BervarHead of Business Development
MergerMotives GmbH - The M&A Consulting Boutique
"Customized support for Mergers & Acquisitions, In- and Outlicensing, Business Development and other related areas".
We are a small and specialized M&A consulting boutique with a young and innovative mindset that is advising and supporting its clients in Mergers & Acquisitions, In- and Outlicensing, Business Succession, Business Development and other related areas. Our clients are companies from various industries all around the world that either do not have their own Business Development team or that need some additional temporary resources for their M&A team.
Mr Adrian PflugshauptManaging Partner
Mundipharma is a global, independent network empowered locally.
We are an asset led, privately owned business, with international presence and in-depth knowledge of the local market.
Our network of independent affiliated companies enables us to leverage our integrated capabilities from discovery to product commercialization.
Built on a tradition of entrepreneurship, our flexibility and way of doing things have allowed us to forge a solid and trustful relationship with our partners, ensuring the sustained success of our business.
Focused on delivering commercial excellence, we actively evaluate opportunities to complement our existing product portfolio, to substantially improve patient’s quality of life.